Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 261.33
ARDM's Cash to Debt is ranked higher than
76% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. ARDM: 261.33 )
Ranked among companies with meaningful Cash to Debt only.
ARDM' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 5.38 Max: No Debt
Current: 261.33
Equity to Asset 0.72
ARDM's Equity to Asset is ranked higher than
65% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ARDM: 0.72 )
Ranked among companies with meaningful Equity to Asset only.
ARDM' s Equity to Asset Range Over the Past 10 Years
Min: -1.83  Med: 0.53 Max: 0.93
Current: 0.72
-1.83
0.93
F-Score: 2
Z-Score: -8.89
M-Score: -1.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -27.40
ARDM's Operating margin (%) is ranked lower than
85% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.51 vs. ARDM: -27.40 )
Ranked among companies with meaningful Operating margin (%) only.
ARDM' s Operating margin (%) Range Over the Past 10 Years
Min: -9165.74  Med: -478.31 Max: -11.49
Current: -27.4
-9165.74
-11.49
Net-margin (%) -27.61
ARDM's Net-margin (%) is ranked lower than
85% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.44 vs. ARDM: -27.61 )
Ranked among companies with meaningful Net-margin (%) only.
ARDM' s Net-margin (%) Range Over the Past 10 Years
Min: -9007.17  Med: -280.05 Max: 13.86
Current: -27.61
-9007.17
13.86
ROE (%) -23.30
ARDM's ROE (%) is ranked lower than
81% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. ARDM: -23.30 )
Ranked among companies with meaningful ROE (%) only.
ARDM' s ROE (%) Range Over the Past 10 Years
Min: -808.13  Med: -183.67 Max: 12.78
Current: -23.3
-808.13
12.78
ROA (%) -16.68
ARDM's ROA (%) is ranked lower than
81% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. ARDM: -16.68 )
Ranked among companies with meaningful ROA (%) only.
ARDM' s ROA (%) Range Over the Past 10 Years
Min: -102.39  Med: -62.71 Max: 8.91
Current: -16.68
-102.39
8.91
ROC (Joel Greenblatt) (%) -1994.49
ARDM's ROC (Joel Greenblatt) (%) is ranked lower than
93% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.81 vs. ARDM: -1994.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARDM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3534.16  Med: -552.13 Max: 1095.34
Current: -1994.49
-3534.16
1095.34
Revenue Growth (3Y)(%) 137.60
ARDM's Revenue Growth (3Y)(%) is ranked higher than
99% of the 581 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ARDM: 137.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARDM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -81.3  Med: -12.50 Max: 137.6
Current: 137.6
-81.3
137.6
» ARDM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ARDM Guru Trades in Q4 2014

First Eagle Investment 3,854,730 sh (unchged)
» More
Q1 2015

ARDM Guru Trades in Q1 2015

Steven Cohen 321,485 sh (New)
First Eagle Investment 3,854,730 sh (unchged)
» More
Q2 2015

ARDM Guru Trades in Q2 2015

First Eagle Investment 3,854,730 sh (unchged)
Steven Cohen 321,485 sh (unchged)
» More
Q3 2015

ARDM Guru Trades in Q3 2015

First Eagle Investment 3,854,730 sh (unchged)
Steven Cohen 320,585 sh (-0.28%)
» More
» Details

Insider Trades

Latest Guru Trades with ARDM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.55
ARDM's P/B is ranked higher than
73% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.50 vs. ARDM: 1.55 )
Ranked among companies with meaningful P/B only.
ARDM' s P/B Range Over the Past 10 Years
Min: 0.76  Med: 3.05 Max: 215
Current: 1.55
0.76
215
P/S 1.58
ARDM's P/S is ranked higher than
68% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. ARDM: 1.58 )
Ranked among companies with meaningful P/S only.
ARDM' s P/S Range Over the Past 10 Years
Min: 1.21  Med: 8.09 Max: 145.45
Current: 1.58
1.21
145.45
PFCF 84.00
ARDM's PFCF is ranked lower than
82% of the 492 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.39 vs. ARDM: 84.00 )
Ranked among companies with meaningful PFCF only.
ARDM' s PFCF Range Over the Past 10 Years
Min: 11.31  Med: 27.64 Max: 397.5
Current: 84
11.31
397.5
Current Ratio 5.52
ARDM's Current Ratio is ranked higher than
82% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. ARDM: 5.52 )
Ranked among companies with meaningful Current Ratio only.
ARDM' s Current Ratio Range Over the Past 10 Years
Min: 0.94  Med: 4.16 Max: 21.99
Current: 5.52
0.94
21.99
Quick Ratio 5.52
ARDM's Quick Ratio is ranked higher than
84% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. ARDM: 5.52 )
Ranked among companies with meaningful Quick Ratio only.
ARDM' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 4.11 Max: 21.99
Current: 5.52
0.94
21.99
Days Sales Outstanding 2.24
ARDM's Days Sales Outstanding is ranked higher than
98% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.67 vs. ARDM: 2.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARDM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.46  Med: 14.93 Max: 571.49
Current: 2.24
3.46
571.49

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.82
ARDM's Price/Net Cash is ranked higher than
88% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.54 vs. ARDM: 1.82 )
Ranked among companies with meaningful Price/Net Cash only.
ARDM' s Price/Net Cash Range Over the Past 10 Years
Min: 1.47  Med: 6.02 Max: 362.93
Current: 1.82
1.47
362.93
Price/Net Current Asset Value 1.72
ARDM's Price/Net Current Asset Value is ranked higher than
91% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.77 vs. ARDM: 1.72 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARDM' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.44  Med: 4.43 Max: 88.72
Current: 1.72
1.44
88.72
Price/Tangible Book 1.55
ARDM's Price/Tangible Book is ranked higher than
80% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.88 vs. ARDM: 1.55 )
Ranked among companies with meaningful Price/Tangible Book only.
ARDM' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.25  Med: 3.26 Max: 190
Current: 1.55
1.25
190
Price/Projected FCF 2.65
ARDM's Price/Projected FCF is ranked lower than
55% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. ARDM: 2.65 )
Ranked among companies with meaningful Price/Projected FCF only.
ARDM' s Price/Projected FCF Range Over the Past 10 Years
Min: 5.67  Med: 9.03 Max: 73.77
Current: 2.65
5.67
73.77
Price/Median PS Value 0.19
ARDM's Price/Median PS Value is ranked higher than
98% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. ARDM: 0.19 )
Ranked among companies with meaningful Price/Median PS Value only.
ARDM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 0.79 Max: 16.85
Current: 0.19
0.15
16.85
Earnings Yield (Greenblatt) (%) -90.45
ARDM's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 720 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ARDM: -90.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARDM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -90.45  Med: 437.20 Max: 6897.8
Current: -90.45
-90.45
6897.8

More Statistics

Revenue(Mil) $31
EPS $ -0.60
Beta0.50
Short Percentage of Float0.86%
52-Week Range $2.96 - 7.90
Shares Outstanding(Mil)14.76

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Aradigm Corp, a California corporation was incorporated on January 30, 1991 . It is a specialty pharmaceutical company engaged in the development and commercialization of drugs delivered by inhalation for the treatment and prevention of severe respiratory diseases. The Company's development candidates include proprietary formulations of the potent antibiotic ciprofloxacin or Pulmaquin ARD-3150 and Lipoquin ARD-3100 that are delivered by inhalation for the management of infections associated with the severe respiratory diseases such as non-cystic fibrosis bronchiectasis and cystic fibrosis. Its proprietary programs under development include, Inhaled Ciprofloxacin and Smoking Cessation Therapy. Ciprofloxacin has been approved by the FDA as an anti-infective agent and is widely used for the acute treatment of a variety of bacterial infections, including exacerbations associated with pulmonary infections. ARD-1600 Inhaled Nicotine is used for Smoking Cessation Therapy. It competes with pharmaceutical and biotechnology companies, hospitals, research organizations, individual scientists and nonprofit organizations engaged in the development of drugs and other therapies for the respiratory disease indications. It had 74 issued United States patents, with 14 additional United States patent applications pending. The research, development, testing, manufacturing, labeling, advertising, promotion, distribution, marketing and export, among other things, of any products it develops are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for ARDM

Headlines

Articles On GuruFocus.com
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 
Eveillard’s First Eagle Seizes 45% of Pharamaceutical Company, Aradigm Dec 19 2012 

More From Other Websites
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2016... Feb 02 2016
Aradigm to Host Corporate Update Conference Call on January 6 Jan 05 2016
Aradigm to Host Corporate Update Conference Call on January 6 Jan 05 2016
Aradigm Corp.: Sudden move in price, will it continue? Dec 23 2015
Aradigm Corp. Earnings Analysis: Q3, 2015 By the Numbers Dec 21 2015
ARADIGM CORP Financials Dec 08 2015
How it All Plays Out - Research on Aradigm, Ideal Power, CareDx, and Colony Bankcorp Dec 03 2015
ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 12 2015
ARADIGM CORP Files SEC form 10-Q, Quarterly Report Nov 12 2015
Aradigm Announces Third Quarter 2015 Financial Results Nov 11 2015
Aradigm reports 3Q loss Nov 11 2015
Aradigm reports 3Q loss Nov 11 2015
Aradigm Announces Third Quarter 2015 Financial Results Nov 11 2015
Aradigm Corp. – Value Analysis (NASDAQ:ARDM) : October 30, 2015 Oct 30 2015
Aradigm Corporation Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic... Oct 13 2015
Aradigm to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29 Sep 23 2015
Aradigm to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29 Sep 23 2015
Aradigm Corporation Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis... Sep 22 2015
Aradigm Corporation Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis... Sep 22 2015
Results from Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm's Liposomal... Sep 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK